Alzheimer’s Association holds three-part education and support series for people with early stage memory loss or dementia

BUFFALO, N.Y. (February 5, 2026) - The Western New York Chapter of the Alzheimer’s Association will hold a three-part educational series in February and March for people who have been diagnosed with early stage memory loss, mild cognitive impairment (MCI), or early stage dementia, and their loved ones.

The free classes, “Living with Early Stage Dementia and MCI,” will take place on February 20, March 6 and March 13. Pre-screening is necessary to take part in the program.

The three-part series will allow participants to ask questions, learn more about their diagnosis and symptoms, and discover the many resources available to them, in a comfortable and confidential setting.

Topics will include:

  • coping with changes and a new diagnosis

  • how to share the diagnosis with family and friends

  • communication techniques

  • disease education and disease progression

  • legal and financial information

  • safety topics

  • discussing routine and how to live a fulfilling life after diagnosis

  • what supports and resources are available

PRE-SCREENING IS REQUIRED. Call 800.272.3900 for more information.  

This program is funded through Dobrak & Fial Funds administered by the Community Foundation for Greater Buffalo.

To learn more about Alzheimer’s disease or other dementias, call 800.272.3900 or visit alz.org.

Alzheimer's Association®

The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementiaTM. Visit alz.org or call 800.272.3900.

Previous
Previous

Free Webinar Examines Impact of Dementia on Black Americans

Next
Next

Roswell Park Team Exploring Promising Biomarker for Tracking Breast Cancer Response to CDK4/6 Therapy